A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer (Q33165699)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

23 July 2017

A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer (English)

1 reference

Europe PubMed Central

23 July 2017

Khandan Keyomarsi

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947565%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Zahi Mitri

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947565%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Cansu Karakas

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947565%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Caimiao Wei

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947565%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Brian Briones

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947565%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Holly Simmons

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947565%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Nuhad Ibrahim

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947565%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Ricardo Alvarez

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947565%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

James L Murray

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947565%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Stacy Moulder

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947565%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

publication date

7 May 2015

1 reference

Europe PubMed Central

23 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947565%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

33

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947565%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947565%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

890-894

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947565%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

https://scigraph.springernature.com/pub.10.1007/s10637-015-0244-4

0 references

Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0244-4

21 January 2018

Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0244-4

21 January 2018

Cyclin E and survival in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0244-4

21 January 2018

The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0244-4

21 January 2018

Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0244-4

21 January 2018

Tumor-specific hyperactive low-molecular-weight cyclin E isoforms detection and characterization in non-metastatic colorectal tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0244-4

21 January 2018

Cyclin E deregulation alters the biologic properties of ovarian cancer cells.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0244-4

21 January 2018

Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0244-4

21 January 2018

Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0244-4

21 January 2018

Targeting low molecular weight cyclin E (LMW-E) in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0244-4

21 January 2018

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0244-4

21 January 2018

Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0244-4

21 January 2018

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0244-4

21 January 2018

Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0244-4

21 January 2018

Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0244-4

21 January 2018

Dose-finding in phase I clinical trials based on toxicity probability intervals.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0244-4

21 January 2018

Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0244-4

21 January 2018

Identifiers

10.1007/S10637-015-0244-4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947565%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947565%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33165699&oldid=1584112562"